The global chemotherapy-induced myelosuppression treatment market stands at a net worth of USD 8.06 Billion in 2022, and is predicted to rise at a CAGR of 3.3% over the forecast period to attain a valuation of USD 9.78 Billion by 2028.
| Attributes | Details |
|---|---|
| Chemotherapy-Induced Myelosuppression Treatment Market Size (2022) | USD 8.06 Billion |
| Sales Forecast (2028) | USD 9.78 Billion |
| Global Market Growth Rate (2022 to 2028) | 4.6% CAGR |
| Share of Top 5 Market Players | 50% |
Chemotherapy-induced myelosuppression treatment accounted for 6.5% share of the global cancer immunotherapy market in 2021.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 3.23% |
| H1, 2022 Projected | 3.26% |
| H1, 2022 Outlook | 3.16% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 07 ↓ |
The market for chemotherapy-induced myelosuppression treatment is subject to changes as per regulatory dynamics and product safety impositions, in lieu of the macro and industry standards.
The comparative analysis and market growth rate of global chemotherapy-induced myelosuppression treatment market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, and, a negative BPS growth is expected in H1-2022 over H1- 2021 duration with 07 Basis Point Share (BPS).
The dip in the BPS values is associated with increased healthcare resource utilization for the treatment of chemotherapy induced myelosuppression, thus incurring high costs associated with treatment. With increasing use of supportive care interventions and associated burden of cost to the patient, the market observed a decline in the BPS values, owed to lower patient preference for the treatment modality.
The key development in the market includes the introduction of COSELA™ (trilaciclib), which is the first approved myeloprotection therapy. With the advent of novel therapies for chemotherapy-induced myelosuppression treatment, the market is expected to observe a positive growth outlook during the forecast period.
Need for Early Diagnosis & Reduction in Cancer Mortality Driving Market Growth
During the historical period of 2013 to 2021, the chemotherapy-induced myelosuppression treatment market expanded at a CAGR of 3%.
Chemotherapy-induced myelosuppression is lesser ability of bone marrow to produce blood cells (WBC, RBC, and platelets). This mostly occurs in cancer patients as an adverse effect of chemotherapy drugs, especially in those cases that are located near the bone marrow or larger bones with cavities.
Chemotherapy-induced myelosuppression can result in decreased production of red blood cells (anaemia), white blood cells (leukopenia), and platelets (thrombocytopenia).
Significant research & development activities have resulted from the growing incidence of leukaemia, prompting various pharmaceutical and drug corporations to invest in cancer-related research. The rapidly increasing rate of anaemia and thrombocytopenia among the elderly population base will also benefit industry dynamics.
The growth of the chemotherapy-induced myelosuppression treatment market can be majorly attributed to the increasing availability of comparatively cost-effective biosimilars in the chemotherapy-induced myelosuppression treatment market.
The global chemotherapy-induced myelosuppression treatment solutions market is anticipated to rise at a CAGR of 3.3% from 2022 to 2028.
Principal Consultant
Extensive Drug Pipeline Likely to Increase Availability of Cost-Effective Products for Chemotherapy-Induced Myelosuppression Treatment
Growing emphasis on the research and development of drugs and therapies for chemotherapy-induced myelosuppression treatment in conditions such as neutropenia, anaemia and thrombocytopenia, is expected to create significant growth opportunities in the chemotherapy-induced myelosuppression treatment market.
Growing R&D expenditure by pharmaceutical industries for the various drugs used for chemotherapy-induced myelosuppression treatment is expected to boost the product pipeline.
Presence of various clinical-stage pharmaceutical companies, which are focusing on the development of novel drugs for chemotherapy-induced myelosuppression treatment, is expected to be a major forecast impact factor.
Cancer is the second-leading cause of death worldwide. Global availability of advanced treatment options such as chemotherapy, radiotherapy & surgical procedures is also boosting the chemotherapy-induced myelosuppression treatment market.
Early diagnosis of cancer has enhanced the treatment-seeking rate in the developed world, which is, in turn, a major driver of the chemotherapy-induced myelosuppression treatment market.
Chemotherapy-induced myelosuppression treatment holds significant potential for revenue generation in developing countries owing to improving treatment-seeking rates and improving product availability.
Long Process for Approval of Drugs for Myelosuppression Treatment
The market is being disrupted by the lengthy approval procedure for medications for myelosuppression treatment. The high cost of medications, as well as other demanding regulatory processes, are posing further challenges to the market growth.
A metallic taste, redness, muscle aches, and arthralgia, as well as the possibility of allergic responses are all common adverse effects of iron therapy. In addition, loss of patent protection and strong competition may impede market expansion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Rising Investments in R&D for Myelosuppressive Therapies Driving Market Growth in North America
North America is leading the global chemotherapy-induced myelosuppression treatment solutions market. The market will gain traction with significant increase in R&D spending for myelosuppressive therapies and the existence of a well-established healthcare industry.
Rising cancer prevalence, expanded infrastructure, and increased healthcare awareness are some of the reasons driving market expansion in this region. Favorable reimbursement rules, robust commercial operations, and a large patient pool are driving the growth in North America.
Prominent Presence of Cancer Therapeutics Providers in the USA
The market in the USA is likely to expand at a rapid pace over the forecast period. The presence of top cancer therapy providers, large R&D investments, and developed healthcare systems are driving the market growth in the USA
Rising cancer burden in the United States has created numerous growth prospects for top cancer therapeutics providers, resulting in increased product demand.
Rising Penetration of Advanced Cancer Care Treatments
The China chemotherapy-induced myelosuppression treatment products and services market is speculated to exhibit a high growth owing to numerous initiatives taken by various organizations to enhance awareness, educate the public, and raise finances for chronic diseases.
Industrial growth, rising senior population and cancer prevalence, rising disposable income, and rapid deployment of advanced cancer care treatments are all contributing to the market growth in China.
Chemotherapy-Induced Myelosuppression Therapies Widely Employed for Treatment of Neutropenia
Neutropenia indication is expected to account 61.6% share of the chemotherapy-induced myelosuppression treatment market in 2022. The global chemotherapy-induced myelosuppression treatment market is classified into three categories based on the indication: anaemia, neutropenia, and thrombocytopenia.
Neutropenia is a blood disorder characterized by decreased neutrophil counts, which are white blood cells that protect the body from infection. One of the most common side effects of chemotherapy is neutropenia, which can lead to life-threatening infections if left untreated.
Higher Effectiveness of Erythropoietin Stimulating Agents in Myelosuppression Treatment
Market share of erythropoietin stimulating agents will grow as the number of instances of anaemia rises, according to pharmacological class. According to the World Health Organization (WHO), anaemia affects more than 1.62 billion people worldwide, accounting for 24.8% of the total population.
These drugs not only reduce transfusion rates but also enhance cognition. They also reduce the need for blood transfusions and are often used by physicians for their cancer patients undergoing chemotherapy to ensure a better quality of life. Erythropoietin stimulating agents are also commonly utilized to boost red blood cell formation in the bone marrow.
Ley manufacturers of chemotherapy-induced myelosuppression treatment devices are focusing on increasing their geographical footprint as well as launching new products to increase their revenue generation in the chemotherapy-induced myelosuppression treatment market.
For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Value in USD Million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | USA, Canada, Mexico, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Nordic, Spain, Japan, China, India, Malaysia, Thailand, Australia, GCC Countries, South Africa, Turkey |
| Key Market Segments Covered | Indication, Drug Class, Route of Administration, Distribution Channel, Region |
| Key Companies Profiled | Novartis AG; Amgen Inc.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Myelo Therapeutics GmbH; Janssen Global Services, LLC; Mission Pharmacal Company; Partner Therapeutics, Inc. |
| Pricing | Available upon Request |
The global chemotherapy-induced myelosuppression treatment market is valued at USD 8.06 Billion in 2022, and is projected to reach USD 9.78 Billion by 2028.
Novartis AG, Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Myelo Therapeutics GmbH are key players in the market.
Increasing prevalence of cancer across the globe coupled with rising aging population and growing preference for chemotherapy are factors driving market growth.
Neutropenia accounts for 61.6% share of the chemotherapy-induced myelosuppression treatment market.
The market is estimated to exhibit a CAGR of 3.3% during the forecast period (2022 to 2028).
1. Executive Summary 2. Market Introduction 3. Chemotherapy-Induced Myelosuppression Treatment Market Opportunity Analysis 4. Market Background 4.1. Drivers 4.2. Restraints 4.3. Trends 5. Macroeconomic Assumptions 6. Global Economic Outlook 7. Key Inclusions 7.1. Key Regulations 7.2. Pipeline Assessment 7.3. Patient Treatment Regimen/Patient Journey 8. Global Market Analysis 2013 to 2021 and Forecast 2022 to 2028 9. North America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 10. Latin America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 11. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 12. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 13. Asia Pacific excluding China (APEC) Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 14. Japan Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 15. MEA Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 16. Forecast Factors: Relevance and Impact 17. Forecast Assumptions 18. Competition Analysis 18.1. Amgen Inc. 18.2. Novartis AG 18.3. Teva Pharmaceutical Industries Ltd 18.4. Mylan N.V. 18.5. Pfizer Inc. 18.6. Janssen Global Services, LLC (Johnson & Johnson) 18.7. Partner Therapeutics, Inc. 18.8. Mission Pharmacal Company 18.9. Myelo Therapeutics GmbH 18.10. Dova Pharmaceutical 19. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Region 19.1. North America 19.2. Latin America 19.3. Western Europe 19.4. Eastern Europe 19.5. Asia Pacific excluding Japan 19.6. Japan 19.7. Middle East and Africa 20. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Drug Class 20.1. Growth Factors 20.1.1. Granulocyte Colony-Stimulating Factor 20.1.2. Thrombopoietin Receptor Agonists 20.2. Erythropoietin-stimulating Agents 20.2.3. Thrombopoietic Agents 20.2.4. Iron supplementation 20.2.5. Others 21. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Route of Administration 21.1. Oral 21.2. Injectable 22. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Indication 22.1. Anemia 22.2. Neutropenia 22.3. Thrombocytopenia 23. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Distribution Channel 23.1. Hospital Pharmacies 23.2. Retail Pharmacies 23.3. Drug Stores 23.4. Online Pharmacies 24. Research Methodology
Explore Healthcare Insights
View Reports
Chemotherapy-Induced Myelosuppression Treatment Market
